Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Medigene

This page shows the latest Medigene news and features for those working in and with pharma, biotech and healthcare.

Roivant forms Asian cell therapy ‘vant’, with Medigene’s help

Roivant forms Asian cell therapy ‘vant’, with Medigene’s help

Dolores Schendel. “T cell receptors are the scouts of the immune system - they help T cells recognize and destroy cancer cells,” said Dolores Schendel, Medigene’s chief scientific officer. ... This partnership implements Medigene’s strategy to

Latest news

  • Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more

    It's not just the GDPR's big day, plus news from Medigene and Pfizer. ... We are grateful for this strong demonstration of confidence in Medigene as a global leader in T cell immunology.".

  • Medigene buys cancer vaccine start-up Medigene buys cancer vaccine start-up

    The new Medigene will combine proprietary immunotherapy platforms with late stage drug candidates and a marketed product," said Medigene chief executive Frank Mathias. ... The Trianta team will be merged into Medigene and its managing director,

  • CMPT announces CEO and loan investment

    He has held roles at Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore) and, most recently, was senior vice president for business development and corporate strategy at Medigene and CEO of Roji

  • Astellas acquires European rights for Eligard

    MediGene sells full European marketing and distribution rights to Eligard for 25m and ongoing royalties. ... MediGene will also receive single-digit royalties on future net European product sales.

  • A competitive edge

    Veregen (Medigene AG). Genital warts . Germany. Silodosin . Urief (Kissei Pharmaceutical)  . Dysuria . South Korea.  . HIV integrase inhibitors. HIV integrase inhibitors are another relatively new antiretroviral drug class designed to block the

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Firstly reviewing the licences and collaborations:. bluebird bio gained access to Medigene's T cell receptor platform for the development of TCR cancer immunotherapy candidates for four indications (not disclosed) Bluebird ... 1, 695. Medigene /Bluebird

  • Pharma deals during January 2014 Pharma deals during January 2014

    An interesting biotech:biotech deal was the acquisition of Trianta by Medigene, although the value at $8m does not feature in our top table.

  • Interview: Yoshihiko Hatanaka, CEO and president, Astellas Interview: Yoshihiko Hatanaka, CEO and president, Astellas

    It acquired the European marketing rights to Eligard, a prostate cancer drug, from MediGene via this route and is co-developing a compound for acute myeloid leukaemia with Ambit.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Pharma industry appointments Pharma industry appointments

    His career history has seen him serve as interim chief financial officer and chief operating officer of Medigene, a German biotech company.

  • Dave Lemus joins Proteros as an executive board member Dave Lemus joins Proteros as an executive board member

    He joins the German biotech’s board from Medigene. Proteros, a private biotech based in Germany, has appointed Dave Lemus as an executive board member, chief operating officer and chief financial ... Prior to his new roles, Lemus was chief operating

  • Apeiron bolsters management board Apeiron bolsters management board

    During the course of his career, Llewellyn-Davies supported Medigene’s strategy to form an immunotherapy company and he assisted in initial public offerings for Wilex.

  • Lanthio Pharma bolsters management team Lanthio Pharma bolsters management team

    Prior to this, he held the role of chief medical and development officer at both Medigene and TopoTarget, and served as a medical director at MorphoSys.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...

Quick links